Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study for ABBV-RGX-314, a VEGF pathway inhibitor developed in partnership with AbbVie (NYSE: ABBV) for the treatment of wet age-related macular degeneration (wet AMD). The therapy is designed to be administered as a one-time injection, aiming to alleviate the frequent intravitreal injection requirements associated with current anti-VEGF treatment regimens.
The data demonstrated that ABBV-RGX-314 was well tolerated, with only mild or moderate adverse events reported by participants. Over the course of six months, the study showed that best corrected visual acuity (BCVA) and central retinal thickness (CRT) were maintained, indicating the potential for a durable response to the treatment.
In addition to wet AMD, the gene therapy is under investigation for other chronic retinal conditions, including diabetic retinopathy, highlighting its broad application potential in ophthalmic care.- Flcube.com
